Telix Pharmaceuticals is trading 4.23% down at A$16.08 as investors continue reassessing dilution from its proposed ITM acquisition.
- The US$1.65 billion transaction would issue approximately 105.8 million new shares, giving ITM shareholders about 23.7% of Telix after completion.
- The mostly share-funded structure has renewed concern that existing holders’ ownership will be diluted, outweighing strategic benefits.
- Broader biotech weakness and higher yields added pressure, but acquisition-related dilution remains the clearest catalyst.